BrainCheck vs Neurotrack (2026)
Two cognitive screens for primary care and population programs, split by depth of evidence against breadth of distribution. BrainCheck publishes validation with sensitivity and specificity reported honestly, reimbursement guidance naming actual CPT codes, and a regulatory position stated completely: a Class II, 510(k) exempt assessment aid, indicated as an aid rather than a stand alone diagnostic. Neurotrack is built for reach: three minute assessments on any device, sized for a Medicare Annual Wellness Visit, with Smart Logic choosing which tests to give and surfacing a DSM 5 aligned diagnostic pathway and a draft care plan, and it sells to health plans as documentation for risk adjustment and in home assessments. Neurotrack describes the product as FDA registered, which is not clearance, while marketing it to help providers diagnose, and it does not say how Smart Logic works. If your failure mode is validated accuracy and a billable path, start with BrainCheck. If your failure mode is screening a whole population inside existing workflows, Neurotrack fits the workflow, and its regulatory position is the first question to put to it.
- The published validation reports sensitivity and specificity honestly, including the weaker figures, and it maps to what the product is indicated for.
- The reimbursement path is published: specific CPT codes, time based minimums and telehealth eligibility in an annually updated guide. Product pricing is not published.
- The regulatory position is stated completely: BrainCheck Assess is a Class II, 510(k) exempt computerised cognitive assessment aid, named as the single regulated component and indicated as an aid rather than as a stand alone diagnostic.
- Population scale deployment is the design: cloud based, running on any device with no specialized hardware, with a first step of about three minutes taken in clinic, remotely or at home, sized to fit inside a Medicare Annual Wellness Visit.
- It sells to health plans as well as providers, positioning the assessments as documentation for V28 risk adjustment, Medicare Advantage in home health risk assessments and Annual Wellness Visits, with named customers including Sutter Health and Desert Oasis Healthcare.
- Neurotrack states SOC 2 and HIPAA directly on the product, and reports 94 percent sensitivity and 90 percent specificity for two of its assessments in a peer reviewed study comparing healthy people with people diagnosed with Alzheimer's disease.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BrainCheck and Neurotrack are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BrainCheck | Neurotrack |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2015 | 2012 |
| Headquarters | Austin, Texas, United States | Redwood City, California, United States |
| Website | braincheck.com | neurotrack.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Digital cognitive assessment and care planning platform. The flagship product, BrainCheck Assess, is a Class II, 510(k)-exempt computerized cognitive assessment aid regulated by the FDA, indicated as an aid in the assessment of cognitive impairment and explicitly not intended as a standalone diagnostic tool.
Source: AI Health Index, September 2026
Neurotrack describes itself as a cognitive care enablement platform: digital cognitive assessments, an adaptive layer it calls Smart Logic, and care planning support, sold to help providers assess, diagnose and care for people with mild cognitive impairment and dementia. The assessments are Symbol Match (processing speed and visual attention), Path Points (a digital trail making task for executive function) and Word Recall (verbal memory); the first step takes about three minutes and can be taken in clinic, remotely or at home.
Source: AI Health Index, September 2026
Questions buyers ask
How do BrainCheck and Neurotrack work with the EHR?
For BrainCheck, the named list stops at those two, and the company notes some feature availability is determined by EHR integration, meaning capability varies by platform.
The platform page says Neurotrack integrates directly into existing EHR environments, connects to major EHR platforms, and generates structured documentation that flows automatically into the patient record, including assessment results, DSM-5 aligned documentation and care plans. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
How do BrainCheck and Neurotrack handle patient data?
Assessment data is handled under role based access controls with activity logging, encrypted in transit and at rest, and BrainCheck states that retention and deletion can be aligned to customer contractual requirements.
For Neurotrack, the rest of the lifecycle is looser. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
What evidence is published for BrainCheck and Neurotrack?
With BrainCheck, a later analysis found a Pearson correlation of 0.77 against the Montreal Cognitive Assessment with a confidence interval reported. A 529 participant study across four United States clinical sites, run with BrainBox Solutions and registered as NCT04423198, tested test retest reliability and concurrent validity against the corresponding paper instruments.
In Neurotrack's case, the published evidence the platform page cites is a Frontiers in Aging Neuroscience study reporting 94 percent sensitivity and 90 percent specificity for the Symbol Match and Path Points battery, comparing healthy people with people diagnosed with Alzheimer's disease. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
How much do BrainCheck and Neurotrack leave to the clinician?
For BrainCheck, the company states that the assessment is not intended for use as a standalone diagnostic tool, that it is designed to support clinical interpretation rather than replace it, and that structured cognitive data is meant to be read alongside history, examination findings and functional status rather than in isolation.
With Neurotrack, the page says Smart Logic supports clinical decision making and never directs it, and that the clinician leads the diagnosis and care plan. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
BrainCheck's evidence is the stronger and more current of the two. Neurotrack's headline figure compares healthy people with people already diagnosed with Alzheimer's disease, which is easier than finding mild impairment, the stage the product is sold to catch, and its deployment figures report more diagnoses without saying how many were confirmed.
On regulatory position BrainCheck states its status completely. Neurotrack describes itself as an FDA registered Class II device while marketing the product to help providers assess, diagnose and care for people with mild cognitive impairment and dementia. Registration is not clearance, and no 510(k) or De Novo is named.
Neurotrack also tells buyers that every result is clinically defensible, without publishing how Smart Logic chooses assessments or what moves a patient onto the diagnostic pathway. On assurance both name something: Neurotrack states SOC 2 and HIPAA on the product, and BrainCheck holds independently assessed certifications including HITRUST, with the artifacts behind a request. Neither publishes pricing, and BrainCheck publishes a policy of not enumerating its model supply chain rather than staying silent about it.
Ask Neurotrack for accuracy at the mild impairment stage against a clinical reference standard, the confirmation rates behind its diagnosis figures, and what its registration covers. Ask BrainCheck for pricing and its business associate agreement.